Diagens Biotechnology Releases Universal Medical Imaging Large Model, Covering 90% of Clinical Scenarios

Deep News
09/26

On the morning of September 26, during the debut showcase session of the Fourth Global Digital Trade Expo, Diagens Biotechnology unveiled its self-developed iMedImage™, the world's largest-parameter universal medical imaging large model. The model completed pre-training based on 80 million data points, supports 19 modalities including chromosomes, CT, and MRI, covers over 90% of clinical scenarios, and demonstrates strong universality and high scalability.

At the event, the Diagens Biotechnology team demonstrated a "zero-code, automated" model training process, showcasing comprehensive capabilities from data import to model generation. According to reports, compared to traditional specialized models, iMedImage™ requires only hundreds of images and several days of training to build disease-specific models, significantly reducing data dependency and cutting development costs by over 90%.

The model has previously received the Sullivan Global Medical Imaging Foundation Large Model Innovation Award. A representative from Diagens Biotechnology stated that iMedImage™, leveraging a "Model as a Service" platform, significantly lowers the application threshold for AI in medical research and clinical practice.

During the exhibition, Diagens Biotechnology also signed strategic cooperation agreements with Wutong Tree, Inspur Group, and ZTE Corporation to jointly advance the research transformation and industrial implementation of AI medical imaging.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10